Oncology

News

New data at EHA backs Sanofi, Innate’s NK cell engager

One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to

News

FDA widens label for BMS’ cancer drug Augtyro

Bristol-Myers Squibb has claimed FDA approval for a new, tumour-agnostic indication for Augtyro, the cancer drug it acquired as part of its $4.1 billion takeover of Turning Point Therapeuti

Oncology

Four takeaways from ASCO24

Last weekend, I travelled to Chicago for the annual conference of the American Society of Clinical Oncologists— the annual event where major breakthroughs in cancer care are announced.

Oncology

Building resilience in cancer trials

Clinical trials are a cornerstone of oncology research, vital for turning scientific breakthroughs into effective cancer treatments.

R&D

ASCO 2024 - Suzanne Trudel

Sometimes getting a new drug to market is a relatively straight line, but sometimes it’s a winding road.

News

Geron finally brings a drug to market as FDA clears Rytelo

More than 30 years after it was first founded, Geron has claimed FDA approval for its first product – myelodysplastic syndromes (MDS) treatment Rytelo.

New data at EHA backs Sanofi, Innate’s NK cell engager

FDA widens label for BMS’ cancer drug Augtyro

Four takeaways from ASCO24

Building resilience in cancer trials

ASCO 2024 - Suzanne Trudel

Geron finally brings a drug to market as FDA clears Rytelo

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Oncology

Editor's Picks